Developer docs
API playgroundTry for free, no card

Search company profiles

Aspen Neuroscience

Full company profile

uuid00007im

Namestring
Aspen Neuroscience
Legal namestring
Aspen Neuroscience, Inc.
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autologous cell therapy, iPSC-derived therapies, regenerative medicine, Parkinson's disease treatment, neuron replacement therapy
Industry3 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Autologous Cell Therapy Commercialization
TypeOne Time License
Description

Aspen Neuroscience is a pre-revenue clinical-stage company developing personalized autologous iPSC-derived cell therapies. The primary revenue stream will come from commercialization of ANPD001 (sasineprocel) for Parkinson's disease treatment upon FDA approval. The company is preparing for commercial launch with the appointment of a Chief Commercial Officer and expansion of manufacturing capabilities.

aspenneuroscience.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 record
1Sasineprocel (ANPD001)
Description

Autologous iPSC-derived dopaminergic neuron precursor cell (DANPC) therapy for Parkinson's disease; replaces lost dopamine-producing neurons via image-guided intracranial injection without requiring immunosuppressive drugs

aspenneuroscience.com
Core offering1 text field

Aspen Neuroscience develops personalized autologous cell replacement therapies derived from a patient's own induced pluripotent stem cells (iPSCs), beginning with ANPD001 (Sasineprocel) for moderate-to-advanced Parkinson's disease. The therapy uses patient skin cells converted to iPSCs, differentiated into dopaminergic neuron precursors, and administered via image-guided intracranial injection to the putamen without immunosuppression. Manufacturing is conducted at a 22,000 sq. ft. GMP facility in San Diego with proprietary machine-learning-based genomic quality controls at every stage.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Mean Good ON time increased by +2.1 to +2.4 hours at 12 months post-treatment
+5 more records
Product overview1 text field

Aspen Neuroscience is a clinical-stage regenerative medicine biotechnology company developing personalized autologous iPSC-derived cell replacement therapies. The company's lead product is ANPD001, now officially named Sasineprocel, an autologous dopaminergic neuronal precursor cell therapy for Parkinson's disease. The therapy is manufactured using a proprietary platform that converts patient skin cells to iPSCs, then differentiates them into dopamine-producing neurons, administered via image-guided intracranial injection. The company operates GMP manufacturing facilities in San Diego and is conducting the ASPIRO Phase 1/2a clinical trial with plans for Phase 3 advancement.

Product and service1 record
1ANPD001 (Sasineprocel)
CategoryCell Therapy
Description

Autologous dopaminergic neuronal precursor cell (DANPC) therapy derived from the patient's own iPSCs for the treatment of moderate-to-advanced Parkinson's disease, administered via image-guided intracranial injection to the putamen without requiring immunosuppression. Most advanced autologous investigational cell therapy for Parkinson's in the United States, with FDA Fast Track designation and Phase 1/2a ASPIRO trial underway.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-08
Description

Manufacturing collaboration to automate production of dopaminergic neuronal precursor cells (DANPCs) for ANPD001. Mytos provides automated cell manufacturing platform to help Aspen scale production and treat greater numbers of patients.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-08
Description

Collaboration and license agreement to advance automation of the iPSC stage of Aspen's autologous manufacturing platform. Cell X leads development of its Celligent platform including Cx Suite and Colonyze, while Aspen leverages its bioinformatics-based platform and leads all discovery, preclinical, development, and commercialization activities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-06-20
Description

ClearPoint Navigation System used for MRI-guided precision implantation of ANPD001 in the ASPIRO clinical trial, enabling sub-millimeter accuracy in cell transplantation.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-08-24
Description

Partnership to incorporate active digital health monitoring in the Trial-Ready Screening Cohort Study using Rune Labs' software and data analytics for precision neurology.

5Emerald Innovations
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-08-24
Description

Partnership to incorporate passive digital health monitoring using Emerald Innovations' invisible off-body sensors for measuring health analytics in Parkinson's disease patients.

aspenneuroscience.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Century Therapeutics is an emerging cell therapy company developing iPSC-derived allogeneic immune cell therapies for cancer. While focused on oncology, it represents a comparable peer in iPSC-derived engineered cell therapy manufacturing and platform development.

TypeEmerging player
Description

Fate Therapeutics is a clinical-stage cell therapy company developing iPSC-derived off-the-shelf NK and T-cell therapies. Comparable as a peer for iPSC-based cell therapy platforms, GMP manufacturing of engineered cell products, and clinical/commercial readiness for novel modalities.

TypeEmerging player
Description

Sana Biotechnology is developing engineered cell therapies, including iPSC-derived platforms, for cancer and other diseases. Comparable as a peer advancing iPSC-based platforms toward clinical and commercial scale with deep manufacturing and QC expertise.

TypeEmerging player
Description

Lineage Cell Therapeutics (formerly BioTime, which acquired Asterias) develops allogeneic cell transplant therapies including OPC1 for spinal cord injury and programs for CNS indications. Comparable as a peer in CNS cell therapy clinical translation with shared scientific lineage to historical stem cell programs.

TypeOthers
Description

Lonza is a leading contract manufacturer of cell and gene therapies with cell therapy-specific manufacturing services. Aspen's CTO Kim Raineri previously led Lonza cell therapy operations. Relevant as an enabler/infrastructure peer for scalable autologous and allogeneic cell therapy manufacturing rather than a direct product competitor.

TypeBroad incumbent
Description

Bayer acquired BlueRock Therapeutics in 2019 to build a cell therapy franchise including Parkinson's disease, and operates AskBio and other gene/cell therapy assets. As the parent of Aspen's closest direct peer, it competes broadly in the same therapeutic and modality space with far greater resources.

TypeBroad incumbent
Description

Vertex has built a cell therapy program including VX-880 for type 1 diabetes (originally developed by Semma Therapeutics using stem cell-derived islet cells). While targeting a different indication, Vertex demonstrates the commercial viability of stem cell-derived autologous/allogeneic cell therapies at scale.

TypeEmerging player
Description

Sumitomo Pharma (with Kyoto University/CiRA researchers) is developing an iPSC-derived dopaminergic neuron cell therapy for Parkinson's disease in Japan. It represents an emerging global competitor in autologous/allogeneic PD cell therapy with strong academic backing and clinical activity in Asia.

TypeDirect peer
Description

BlueRock Therapeutics (acquired by Bayer for ~$1B in 2019) is the most direct competitor, developing iPSC-derived dopaminergic neuron cell therapies for Parkinson's disease. Both companies target the same indication with stem cell-derived neuron replacement, but BlueRock pursues an off-the-shelf allogeneic approach versus Aspen's autologous model.

TypeEmerging player
Description

Nkarta is a clinical-stage cell therapy company developing allogeneic and autologous NK cell therapies for cancer. Comparable as an emerging peer in cell therapy manufacturing, GMP operations, and clinical pipeline development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors25 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aspen Neuroscience

Aspen Neuroscience firmographics

Firmographics
Name
Aspen Neuroscience
Legal name
Aspen Neuroscience, Inc.
Website
https://aspenneuroscience.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Aspen Neuroscience industry classification

Industry
Product category
Cell Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Autologous cell therapy
  • IPSC-derived therapies
  • Regenerative medicine
  • Parkinson's disease treatment
  • Neuron replacement therapy

Where Aspen Neuroscience is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aspen Neuroscience business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Autologous Cell Therapy Commercialization: Aspen Neuroscience is a pre-revenue clinical-stage company developing personalized autologous iPSC-derived cell therapies. The primary revenue stream will come from commercialization of ANPD001 (sasineprocel) for Parkinson's disease treatment upon FDA approval. The company is preparing for commercial launch with the appointment of a Chief Commercial Officer and expansion of manufacturing capabilities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Aspen Neuroscience product offering

Product offering

Core offering

Aspen Neuroscience develops personalized autologous cell replacement therapies derived from a patient's own induced pluripotent stem cells (iPSCs), beginning with ANPD001 (Sasineprocel) for moderate-to-advanced Parkinson's disease. The therapy uses patient skin cells converted to iPSCs, differentiated into dopaminergic neuron precursors, and administered via image-guided intracranial injection to the putamen without immunosuppression. Manufacturing is conducted at a 22,000 sq. ft. GMP facility in San Diego with proprietary machine-learning-based genomic quality controls at every stage.

Product overview

Aspen Neuroscience is a clinical-stage regenerative medicine biotechnology company developing personalized autologous iPSC-derived cell replacement therapies. The company's lead product is ANPD001, now officially named Sasineprocel, an autologous dopaminergic neuronal precursor cell therapy for Parkinson's disease. The therapy is manufactured using a proprietary platform that converts patient skin cells to iPSCs, then differentiates them into dopamine-producing neurons, administered via image-guided intracranial injection. The company operates GMP manufacturing facilities in San Diego and is conducting the ASPIRO Phase 1/2a clinical trial with plans for Phase 3 advancement.

Differentiator

Problem solved

Functional benefit

Brands

  • Sasineprocel (ANPD001): Autologous iPSC-derived dopaminergic neuron precursor cell (DANPC) therapy for Parkinson's disease; replaces lost dopamine-producing neurons via image-guided intracranial injection without requiring immunosuppressive drugs

Products and services

  • ANPD001 (Sasineprocel) Autologous dopaminergic neuronal precursor cell (DANPC) therapy derived from the patient's own iPSCs for the treatment of moderate-to-advanced Parkinson's disease, administered via image-guided intracranial injection to the putamen without requiring immunosuppression. Most advanced autologous investigational cell therapy for Parkinson's in the United States, with FDA Fast Track designation and Phase 1/2a ASPIRO trial underway.

Quantifiable outcome

  • Mean Good ON time increased by +2.1 to +2.4 hours at 12 months post-treatment
  • +5 more outcomes

Companies that use Aspen Neuroscience

Customer profile

Segments1 record

Ideal customer profiles1 record

Aspen Neuroscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Aspen Neuroscience partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • MytoscoreTechnology or Integration · 8 January 2025Manufacturing collaboration to automate production of dopaminergic neuronal precursor cells (DANPCs) for ANPD001. Mytos provides automated cell manufacturing platform to help Aspen scale production and treat greater numbers of patients.
  • Cell X TechnologiescoreTechnology or Integration · 8 October 2024Collaboration and license agreement to advance automation of the iPSC stage of Aspen's autologous manufacturing platform. Cell X leads development of its Celligent platform including Cx Suite and Colonyze, while Aspen leverages its bioinformatics-based platform and leads all discovery, preclinical, development, and commercialization activities.
  • ClearPoint (MRI-guided Navigation System)coreTechnology or Integration · 20 June 2024ClearPoint Navigation System used for MRI-guided precision implantation of ANPD001 in the ASPIRO clinical trial, enabling sub-millimeter accuracy in cell transplantation.
  • Rune LabsminorStrategic or Co-development Partner · 24 August 2023Partnership to incorporate active digital health monitoring in the Trial-Ready Screening Cohort Study using Rune Labs' software and data analytics for precision neurology.
  • Emerald InnovationsminorStrategic or Co-development Partner · 24 August 2023Partnership to incorporate passive digital health monitoring using Emerald Innovations' invisible off-body sensors for measuring health analytics in Parkinson's disease patients.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Aspen Neuroscience competitors and assessment

Company assessment

Emerging players

  • Century Therapeutics: Century Therapeutics is an emerging cell therapy company developing iPSC-derived allogeneic immune cell therapies for cancer. While focused on oncology, it represents a comparable peer in iPSC-derived engineered cell therapy manufacturing and platform development.
  • Fate Therapeutics: Fate Therapeutics is a clinical-stage cell therapy company developing iPSC-derived off-the-shelf NK and T-cell therapies. Comparable as a peer for iPSC-based cell therapy platforms, GMP manufacturing of engineered cell products, and clinical/commercial readiness for novel modalities.
  • Sana Biotechnology: Sana Biotechnology is developing engineered cell therapies, including iPSC-derived platforms, for cancer and other diseases. Comparable as a peer advancing iPSC-based platforms toward clinical and commercial scale with deep manufacturing and QC expertise.
  • Lineage Cell Therapeutics: Lineage Cell Therapeutics (formerly BioTime, which acquired Asterias) develops allogeneic cell transplant therapies including OPC1 for spinal cord injury and programs for CNS indications. Comparable as a peer in CNS cell therapy clinical translation with shared scientific lineage to historical stem cell programs.
  • Sumitomo Pharma: Sumitomo Pharma (with Kyoto University/CiRA researchers) is developing an iPSC-derived dopaminergic neuron cell therapy for Parkinson's disease in Japan. It represents an emerging global competitor in autologous/allogeneic PD cell therapy with strong academic backing and clinical activity in Asia.
  • Nkarta: Nkarta is a clinical-stage cell therapy company developing allogeneic and autologous NK cell therapies for cancer. Comparable as an emerging peer in cell therapy manufacturing, GMP operations, and clinical pipeline development.

Others

  • Lonza Group: Lonza is a leading contract manufacturer of cell and gene therapies with cell therapy-specific manufacturing services. Aspen's CTO Kim Raineri previously led Lonza cell therapy operations. Relevant as an enabler/infrastructure peer for scalable autologous and allogeneic cell therapy manufacturing rather than a direct product competitor.

Broad incumbents

  • Bayer AG (Cell & Gene Therapy): Bayer acquired BlueRock Therapeutics in 2019 to build a cell therapy franchise including Parkinson's disease, and operates AskBio and other gene/cell therapy assets. As the parent of Aspen's closest direct peer, it competes broadly in the same therapeutic and modality space with far greater resources.
  • Vertex Pharmaceuticals (Cell Therapy): Vertex has built a cell therapy program including VX-880 for type 1 diabetes (originally developed by Semma Therapeutics using stem cell-derived islet cells). While targeting a different indication, Vertex demonstrates the commercial viability of stem cell-derived autologous/allogeneic cell therapies at scale.

Direct peers

  • BlueRock Therapeutics: BlueRock Therapeutics (acquired by Bayer for ~$1B in 2019) is the most direct competitor, developing iPSC-derived dopaminergic neuron cell therapies for Parkinson's disease. Both companies target the same indication with stem cell-derived neuron replacement, but BlueRock pursues an off-the-shelf allogeneic approach versus Aspen's autologous model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Aspen Neuroscience social profiles

Digital presence

Aspen Neuroscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aspen Neuroscience leadership team

Management profile

Number of profiles

Profiles13 records

Aspen Neuroscience funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aspen Neuroscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aspen Neuroscience

What does Aspen Neuroscience do?

Aspen Neuroscience develops personalized autologous cell replacement therapies derived from a patient's own induced pluripotent stem cells (iPSCs), beginning with ANPD001 (Sasineprocel) for moderate-to-advanced Parkinson's disease. The therapy uses patient skin cells converted to iPSCs, differentiated into dopaminergic neuron precursors, and administered via image-guided intracranial injection to the putamen without immunosuppression. Manufacturing is conducted at a 22,000 sq. ft. GMP facility in San Diego with proprietary machine-learning-based genomic quality controls at every stage.

Is Aspen Neuroscience a public or private company?

Aspen Neuroscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aspen Neuroscience founded?

Aspen Neuroscience was founded in 2018. It employs 101 to 250 people.

Where is Aspen Neuroscience based?

Aspen Neuroscience is headquartered in La Jolla, United States, in the North America region.

How does Aspen Neuroscience make money?

One revenue line is on record: autologous Cell Therapy Commercialization.

Who are Aspen Neuroscience's main competitors?

Emerging players on record are Century Therapeutics, Fate Therapeutics, Sana Biotechnology, Lineage Cell Therapeutics, Sumitomo Pharma and Nkarta. Lonza Group is listed as an others. Broad incumbents are Bayer AG (Cell & Gene Therapy) and Vertex Pharmaceuticals (Cell Therapy). BlueRock Therapeutics is listed as a direct peer.

Does Aspen Neuroscience have an API?

No public API is recorded for Aspen Neuroscience.

What industry is Aspen Neuroscience in?

Aspen Neuroscience's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewOrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% StakeOrbiMed Advisors reported beneficial ownership of 12.3% of Aspen Neuroscience's common stock through its private investment fund. The firm acquired shares via preferred-stock conversions and a purchase of 1 million IPO shares at $15 each, stating the investment is for financial purposes, not to take control.In VivoUS Biopharma IPO Total Nears $9bn As Bambusa, Aspen Launch OfferingsBambusa Therapeutics and Aspen Neuroscience launched IPOs, raising $168.9m and $140.6m respectively. This brings US biopharma IPOs to 29 in 2026 with $8.89bn in gross proceeds. The total is far below the record-breaking 2020 and 2021 years.TradingViewBispecific biotech Bambusa and Parkinson’s-focused Aspen slide on trading debutsBambusa Therapeutics and Aspen Neuroscience debuted on Nasdaq, trading lower on Friday. Bambusa's shares fell 7% from its $16 IPO price, while Aspen's fell 20% from $15. Both companies raised proceeds to advance their lead assets.MarketWatchAspen Neuroscience Slides in Initial Trading Following IPOAspen Neuroscience's stock fell 16% to $12.66 midday Friday after its IPO, opening at $14.70. The company sold nearly 9.4 million shares at $15 each, at the low end of the expected $15 to $17 range.MoomooU.S. Stock Market Movements | Clinical-stage biotechnology company Aspen Neuroscience (ASPE.US) lists on U.S. exchanges, shares drop over 17% after openingAspen Neuroscience listed on U.S. exchanges on Friday, with shares trading at $12.345, down over 17% from the $15 IPO price. The clinical-stage biotech, focused on Parkinson's disease stem cell therapy, plans to initiate Phase III patient dosing in the second half of 2027.The future of tradingAspen Neuroscience falls in Nasdaq debut after $141 million US IPOAspen Neuroscience shares fell 6% on Nasdaq debut after a $141 million US IPO, opening at $14.70 versus the $15 IPO price. The San Diego-based developer, which is developing therapies for neurodegenerative diseases, sold 9.38 million shares at the low end of the $15–$17 range. Its lead product candidate, sasineprocel, is in an early- to mid-stage trial for Parkinson's disease.Renaissance CapitalParkinson’s disease biotech Aspen Neuroscience prices IPO at $15, the low end of the rangeAspen Neuroscience priced its IPO at $15, raising $141 million from 9.4 million shares. The Parkinson's biotech's lead candidate, sasineprocel, is in a Phase 1/2a trial with 15 patients dosed, and the company expects a Phase 3 trial in the second half of 2027.MarketWatchAspen Neuroscience Initial Public Offering Priced at Bottom of ViewsAspen Neuroscience's IPO was priced at $15 per share, the low end of the $15–$17 range, raising about $140.6 million. The San Diego clinical-stage biotech is selling nearly 9.4 million shares, with shares trading on Nasdaq under ASPE later Friday.Seeking AlphaAspen Neuroscience prices IPO at $15 per share (ASPE:Pending)Aspen Neuroscience priced its IPO of 9.375 million shares at $15 per share, expecting gross proceeds of about $140.6 million. The company granted underwriters a 30-day option to buy up to 1.406 million additional shares. Shares will trade on Nasdaq on October 30, with the offering expected to close on November 2.FierceBiotechBambusa shoots past IPO targets as Aspen trims offeringBambusa Therapeutics oversubscribed its IPO, selling more shares at the midpoint to gross $168.9 million for bispecific R&D, while Aspen Neuroscience undersubscribed, selling fewer shares to gross about $140.6 million. Bambusa will use the funds to advance BBT001 toward a phase 2b trial, and Aspen plans to invest $110 million in a Parkinson's phase 3 trial.